AUTHORS
Yajun Wang, PhD, Xu Ji, PhD2, Yanliang Bai, PhD3, Jiangxue Hou, MD4, juan wang5, Ping Wang6, sun Wu7, weiling Qin8, junjie Yin9, chao Li, N/A10, Genjie Wang, N/A11, zheng Xu12, shuhao mei13, guochao Ji14, Yaomei Wang, PhD15, Baijun Fang, PhD16, quande Lin, PhD17
AFFILIATIONS
1 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
2 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
3 Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Zhengzhou, China
4 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
5 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
6 Zhumadian Central Hospital, zhumadian, China
7 The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China
8 WeiLingQinXy@163.com, Xinxiang, China
9 Xinxiang Central Hospital, Xinxiang, China
10 Nanyang Central Hospital., Nanyang, China
11 Shangqiu First People’s Hospital, Shangqiu, China
12 Xinyang Central Hospital, Xinyang, China
13 Xuchang Central Hospital, Xuchang, China
14 Puyang People’s Hospital, Puyang, China
15 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
16 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
17 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
ABSTRACT
Introduction
Bortezomib-based induction remains a standard frontline approach for multiple myeloma (MM). However, some patients fail to achieve an adequate early response or develop treatment-related toxicities that limit continuation of the initial regimen. The optimal therapeutic strategy for this clinically challenging population remains uncertain. This multicenter real-world study evaluated the efficacy and safety of early switching to carfilzomib, pomalidomide, and dexamethasone (KPd) in patients with MM with suboptimal early response or intolerance to first-line bortezomib-based induction.
Methods
This retrospective, multicenter, real-world observational study included patients with MM who underwent early switch to KPd after first-line bortezomib-based induction between September 12, 2022, and May 1, 2026. Suboptimal early response was defined as failure to achieve very good partial response (VGPR) after 2 cycles of induction, and intolerance was defined as grade ≥2 adverse events (AEs) according to CTCAE criteria that prevented continuation of the original regimen. KPd consisted of carfilzomib (20/27 mg/m² on days 1, 2, 8, 9, 15, and 16), pomalidomide (4 mg on days 1–21), and dexamethasone (20 mg on days 1, 2, 8, 9, 15, and 16). The primary endpoint was overall response rate (ORR). Secondary endpoints included rates of ≥VGPR, complete response (CR) or better, response deepening, survival outcomes, stem cell collection, and safety.
Results
A total of 77 patients were included. The median age was 63 years (range, 36–80), and 44 patients (57.1%) were male. Early switch to KPd was performed due to suboptimal early response in 42 patients (54.5%), intolerance in 22 (28.6%), and both reasons in 13 (16.9%).After KPd-based sequential therapy, the ORR was 92.2% (71/77), with 59 patients (76.6%) achieving ≥VGPR and 42 patients (54.5%) achieving CR or better. Among these patients, 42 (54.5%) achieved CR or better, 17 (22.1%) achieved VGPR, and 12 (15.6%) achieved partial response. Response deepening was observed in 62 of 77 patients (80.5%). Patients who switched because of intolerance achieved higher rates of ≥VGPR (95.5% vs. 64.3%, P=0.006) and CR or better (77.3% vs. 42.9%, P=0.016) compared with those switched because of suboptimal early response.Fifteen patients underwent autologous stem cell collection, with a median CD34+ cell yield of 8.30×10^6/kg (range, 1.75–21.30×10^6/kg) among 10 patients with available yield data.
Survival analyses were performed in 73 patients. At data cutoff, median progression-free survival (PFS) and overall survival (OS) were not reached. The estimated 12- and 24-month PFS rates were 81.2% and 73.9%, respectively, while the corresponding OS rates were 98.6% and 94.6%. Among patients achieving at least partial response, median duration of response (DOR) was not reached, with estimated 12- and 24-month DOR rates of 83.5% and 76.1%. Among patients achieving CR or better, median duration of complete response (DOCR) was not reached, with estimated 12- and 24-month DOCR rates of 91.3% and 77.5%.
Any-grade AEs occurred in 49 patients (63.6%), and grade ≥3 AEs occurred in 10 patients (13.0%). The most common AEs were anemia (27.3%), infection (18.2%), and arrhythmia (14.3%). No unexpected safety signals were identified.
Conclusions
This multicenter real-world observational study suggests that early switch to KPd in patients with MM with suboptimal early response or intolerance to first-line bortezomib-based induction is associated with high response rates, substantial response deepening, and durable disease control. The safety profile was manageable and consistent with previous clinical studies. These findings support KPd as a feasible early-switch strategy for this clinically challenging population.
DISCLOSURES
Yajun Wang, PhD: No relevant conflicts of interest to declare.